Devonian Health Group (CVE:GSD) Stock Price Down 31.6% – What’s Next?

Devonian Health Group Inc. (CVE:GSD)’s share price dropped 31.6% during trading on Wednesday . The company traded as low as C$0.10 and last traded at C$0.13. Approximately 130,060 shares traded hands during mid-day trading, an increase of 595% from the average daily volume of 18,703 shares. The stock had previously closed at C$0.19.

Devonian Health Group Stock Down 31.6%

The firm has a 50-day moving average of C$0.17 and a two-hundred day moving average of C$0.19. The firm has a market cap of C$19.27 million, a price-to-earnings ratio of -6.50 and a beta of 1.28. The company has a current ratio of 1.07, a quick ratio of 7.82 and a debt-to-equity ratio of 16.36.

Devonian Health Group Company Profile

Devonian Health Group Inc engages in the development of botanical drugs. Its lead product candidate is Thykamine, completed Phase IIa clinical trial product for the treatment of ulcerative colitis and atopic dermatitis. The company also develops Pantoprazole Magnesium for the treatment of gastric; Cleo-35 for the treatment of hormonal acne in women; and value-added products for dermo-cosmetics.